Literature DB >> 4003469

Second-look laparotomy in ovarian cancer: evaluation of pathologic variables.

K C Podratz, G D Malkasian, J F Hilton, E A Harris, T A Gaffey.   

Abstract

From 1977 through 1982, 135 patients with ovarian cancer, having a mean age of 53.7 years and no clinical evidence of disease after approximately 1 year of treatment, underwent a "second-look" laparotomy. Of the 135 patients, 58 (43%) had histologic confirmation of disease at the second-look procedure. Persistent disease was positively correlated with the original stage and negatively correlated with the extent of the original reductive surgery. The original histologic grade or cellular subtype did not significantly influence the findings at reexploration. Patient survival, as judged by percentage of patients alive 3 years after the second-look laparotomy, was dependent on the following surgical/pathologic parameters: tumor size at reexploration, peritoneal cytologic features, residual tumor after reexploration, and histologic grade.

Entities:  

Mesh:

Year:  1985        PMID: 4003469     DOI: 10.1016/s0002-9378(85)80028-4

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  4 in total

1.  Serum CA-125 as a guideline for the timing of a second-look operation and second-line treatment in ovarian cancer.

Authors:  W Jäger; R Adam; L Wildt; N Lang
Journal:  Arch Gynecol Obstet       Date:  1988       Impact factor: 2.344

2.  The value of second-look operation in patients with advanced epithelial ovarian carcinoma.

Authors:  P Sevelda; C Dittrich; H Salzer
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

3.  The role of chemotherapy including ifosfamide for ovarian carcinoma. Austrian Collab. Ovarian Cancer Study Group.

Authors:  K Karrer; H Salzer; P Sevelda; C Dittrich
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trial.

Authors:  T Dell' Anna; M Signorelli; P Benedetti-Panici; A Maggioni; R Fossati; R Fruscio; R Milani; L Bocciolone; A Buda; C Mangioni; G Scambia; R Angioli; E Campagnutta; R Grassi; F Landoni
Journal:  Br J Cancer       Date:  2012-08-02       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.